A Follow-up Study: Acute Behavioural Effects of Delta(9)-THC in Female Heterozygous Neuregulin 1 Transmembrane Domain Mutant Mice

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2010 Jun 24

PMID 20571781

Citations 20

Authors

Leonora E Long

Rose Chesworth

Jonathon C Arnold

Tim Karl

Affiliations

Soon will be listed here.

Abstract

Rationale: Heavy cannabis use is linked with an increased risk for schizophrenia. We showed previously that male heterozygous neuregulin 1 transmembrane domain (Nrg1 HET) mice are more sensitive to some effects of the psychotropic cannabis constituent Delta(9)-tetrahydrocannabinol (THC). We report data from a follow-up study in female Nrg1 HET mice, investigating THC effects on behaviours with some relevance to schizophrenia.

Methods: Mice were injected with THC (0, 5 or 10 mg/kg i.p.) 30 min before a test battery: open field, elevated plus maze, novel object recognition (set 1) or light-dark, social interaction (SI) and prepulse inhibition (PPI 1: variable interstimulus interval (ISI); set 2). Another set (set 3) was injected with the same doses of THC before a fixed interstimulus interval PPI test (PPI 2).

Results: Female Nrg1 HETs displayed the hallmark increased locomotor activity at 5 months and anxiolytic-like behaviour in the open field at 3 and 5 months. THC decreased locomotor activity in both genotypes. THC selectively reduced some SI behaviours in WT mice. Baseline PPI was enhanced in mutants under a variable ISI, while THC had no effect on PPI using either protocol.

Conclusions: This study reports novel findings on the baseline PPI profile and resistance to THC-induced social withdrawal in female Nrg1 HET mice. This is the first description of THC effects in females of this mouse model and suggests that the transmembrane domain Nrg1 mutation does not appear to have a severe impact on the behavioural sensitivity to THC in female mice.

Citing Articles

Impaired extinction of operant cocaine in a genetic mouse model of schizophrenia risk.

Chesworth R, Visini G, Karl T Psychopharmacology (Berl). 2023; 240(7):1531-1546.

PMID: 37233814 PMC: 10271887. DOI: 10.1007/s00213-023-06386-8.

The effects of preventative cannabidiol in a male mouse model of schizophrenia.

Visini G, Brown S, Weston-Green K, Weickert C, Chesworth R, Karl T Front Cell Neurosci. 2022; 16:1010478.

PMID: 36406747 PMC: 9669370. DOI: 10.3389/fncel.2022.1010478.

Δ-9-Tetrahydrocannabinol treatment during adolescence and alterations in the inhibitory networks of the adult prefrontal cortex in mice subjected to perinatal NMDA receptor antagonist injection and to postweaning social isolation.

Garcia-Mompo C, Curto Y, Carceller H, Gilabert-Juan J, Rodriguez-Flores E, Guirado R Transl Psychiatry. 2020; 10(1):177.

PMID: 32488050 PMC: 7266818. DOI: 10.1038/s41398-020-0853-3.

Acute Cannabinoids Produce Robust Anxiety-Like and Locomotor Effects in Mice, but Long-Term Consequences Are Age- and Sex-Dependent.

Kasten C, Zhang Y, Boehm 2nd S Front Behav Neurosci. 2019; 13:32.

PMID: 30842732 PMC: 6391357. DOI: 10.3389/fnbeh.2019.00032.

Behavioral and Pharmacokinetic Profile of Indole-Derived Synthetic Cannabinoids JWH-073 and JWH-210 as Compared to the Phytocannabinoid Δ-THC in Rats.

Uttl L, Szczurowska E, Hajkova K, Horsley R, Stefkova K, Hlozek T Front Neurosci. 2018; 12:703.

PMID: 30405327 PMC: 6206206. DOI: 10.3389/fnins.2018.00703.

References

Ludewig K, Geyer M, Vollenweider F . Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biol Psychiatry. 2003; 54(2):121-8. DOI: 10.1016/s0006-3223(02)01925-x. View

Cha Y, Jones K, Kuhn C, Wilson W, Swartzwelder H . Sex differences in the effects of delta9-tetrahydrocannabinol on spatial learning in adolescent and adult rats. Behav Pharmacol. 2007; 18(5-6):563-9. DOI: 10.1097/FBP.0b013e3282ee7b7e. View

De Bellis M, Keshavan M, Beers S, Hall J, Frustaci K, Masalehdan A . Sex differences in brain maturation during childhood and adolescence. Cereb Cortex. 2001; 11(6):552-7. DOI: 10.1093/cercor/11.6.552. View

Rao M, Kolsch H . Effects of estrogen on brain development and neuroprotection--implications for negative symptoms in schizophrenia. Psychoneuroendocrinology. 2003; 28 Suppl 2:83-96. DOI: 10.1016/s0306-4530(02)00126-9. View

Shifman S, Johannesson M, Bronstein M, Chen S, Collier D, Craddock N . Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet. 2008; 4(2):e28. PMC: 2242812. DOI: 10.1371/journal.pgen.0040028. View

Munafo M, Thiselton D, Clark T, Flint J . Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry. 2006; 11(6):539-46. DOI: 10.1038/sj.mp.4001817. View

Powell S, Geyer M, Gallagher D, Paulus M . The balance between approach and avoidance behaviors in a novel object exploration paradigm in mice. Behav Brain Res. 2004; 152(2):341-9. DOI: 10.1016/j.bbr.2003.10.020. View

Tseng A, Craft R . Sex differences in antinociceptive and motoric effects of cannabinoids. Eur J Pharmacol. 2001; 430(1):41-7. DOI: 10.1016/s0014-2999(01)01267-5. View

Kask A, Nguyen H, Pabst R, von Horsten S . Factors influencing behavior of group-housed male rats in the social interaction test: focus on cohort removal. Physiol Behav. 2001; 74(3):277-82. DOI: 10.1016/s0031-9384(01)00587-x. View

10.

Brebion G, Bressan R, David A, Pilowsky L . Role of processing speed and premorbid IQ on visual recognition in patients with schizophrenia. J Clin Exp Neuropsychol. 2008; 31(3):302-11. DOI: 10.1080/13803390802108362. View

11.

Karl T, Duffy L, Scimone A, Harvey R, Schofield P . Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav. 2007; 6(7):677-87. DOI: 10.1111/j.1601-183X.2006.00298.x. View

12.

Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S . Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002; 71(4):877-92. PMC: 378543. DOI: 10.1086/342734. View

13.

Braff D, Geyer M, Swerdlow N . Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001; 156(2-3):234-58. DOI: 10.1007/s002130100810. View

14.

Mei L, Xiong W . Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008; 9(6):437-52. PMC: 2682371. DOI: 10.1038/nrn2392. View

15.

Kumari V, Aasen I, Sharma T . Sex differences in prepulse inhibition deficits in chronic schizophrenia. Schizophr Res. 2004; 69(2-3):219-35. DOI: 10.1016/j.schres.2003.09.010. View

16.

Harrison P, Tunbridge E . Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology. 2007; 33(13):3037-45. DOI: 10.1038/sj.npp.1301543. View

17.

Harrison P, Law A . Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry. 2006; 60(2):132-40. DOI: 10.1016/j.biopsych.2005.11.002. View

18.

Law A, Lipska B, Weickert C, Hyde T, Straub R, Hashimoto R . Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc Natl Acad Sci U S A. 2006; 103(17):6747-52. PMC: 1458952. DOI: 10.1073/pnas.0602002103. View

19.

File S, Seth P . A review of 25 years of the social interaction test. Eur J Pharmacol. 2003; 463(1-3):35-53. DOI: 10.1016/s0014-2999(03)01273-1. View

20.

Moore T, Zammit S, Lingford-Hughes A, Barnes T, Jones P, Burke M . Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370(9584):319-28. DOI: 10.1016/S0140-6736(07)61162-3. View